<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104180</url>
  </required_header>
  <id_info>
    <org_study_id>LINE4001</org_study_id>
    <secondary_id>2013-A01285-40</secondary_id>
    <nct_id>NCT02104180</nct_id>
  </id_info>
  <brief_title>Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGras</brief_title>
  <official_title>Evaluation of the Non-inferiority of TulleGras M.S.® Versus Urgotul® in Pain Associated With Removal of Wound Dressing During Care of Venous Leg Ulcer. An Open-label, Multicenter, Randomized, Controlled, Crossover Study With Blinded Reading of Healing Criteria.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CEN Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the non-inferiority of TulleGras M.S.® versus Urgotul® in pain associated with
      removal of wound dressing during care of venous leg ulcer
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity at Removal of the Primary Dressing, Evaluated by the Subject Just After Removal</measure>
    <time_frame>at the time of dressing removal on Day 2 (Visit 2) and Day 4 (Visit 3)</time_frame>
    <description>Pain intensity experienced by subjects associated to removal of each study primary dressings during the care, assessed at of the Cross-over Period on a visual analogue scale (VAS). The VAS was provided as a 100 mm, non-graduated horizontal line, with extremities indicating &quot; no pain &quot; (0) and &quot; extreme pain &quot; (100). The subject responded by drawing a vertical line to assess the pain intensity he/she experienced at the time of removal of the primary wound dressing.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>TulleGras M.S.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Urgotul</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Urgotul</intervention_name>
    <description>sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline</description>
    <arm_group_label>Urgotul</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TulleGras M.S.</intervention_name>
    <description>Sterile dressing that consists of viscose tissue coated with mineral vaseline</description>
    <arm_group_label>TulleGras M.S.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject informed of the objectives, purpose, details and constraints of the study and
             who has given his/her written informed consent.

          -  Male or female subject.

          -  Subject at least 45 years of age.

          -  Subject presenting with an open venous leg ulcer.

          -  Age of venous leg ulcer between 1 month and 12 months inclusive at the Inclusion Visit
             (Visit 1).

          -  Venous leg ulcer whose area is between 4 cm2 and 50 cm2 inclusive at the Inclusion
             Visit (Visit 1).

          -  Venous leg ulcer in the granulation phase over 50% of its area at the Inclusion Visit
             (Visit 1);

        Exclusion Criteria:

        Related to the disease studied:

          -  Venous leg ulcer for which surgery is indicated or for which a surgical procedure is
             planned within twelve weeks of inclusion in the study (Visit 1).

          -  Venous leg ulcer at start of cleaning phase;

          -  Fibrinous and dry ulcer (non exudative wound) or on the contrary highly exudative
             and/or hemorrhagic.

          -  Venous leg ulcer with signs of critical colonization or clinically infected.

          -  Cancerous venous leg ulcer.

        Related to the subject:

          -  Subject presenting with a serious systemic disease, which may lead to premature
             termination of the study before the end of the twelve weeks of treatment of the Follow
             up Period.

          -  Subject with a medical history or a significant disease revealed by history which can
             limit his/her participation or prevent the subject from completing the study.

          -  Subject presenting with a progressive neoplasm, treated with radiotherapy or
             chemotherapy or immunosuppressant therapy or high-dose corticosteroids.

          -  Subject who underwent surgery directly related to his/her venous disease during the
             two months prior to Inclusion Visit (Visit 1).

          -  Subject with poorly controlled diabetes.

          -  Subject who presented with a deep venous thrombosis during the 3 months prior to
             Inclusion Visit (Visit 1).

          -  Subject confined to bed.

          -  Woman of child-bearing potential (NOT postmenopausal for at least 24 months or NOT
             surgically sterilized (tubal ligation) or NOT hysterectomized) who is NOT routinely
             using adequate and efficient hormonal contraception or barrier method (intrauterine
             device, diaphragm, combination of condom and spermicide) prior to and during the
             trial.

          -  Subject whose ankle has a circumference, measured at the Inclusion Visit (Visit 1),
             greater than 32 cm (&gt; 32 cm).

          -  Subject presenting with symptomatic or asymptomatic peripheral arterial disease,
             particularly with a distal systolic pressure index, measured at the Inclusion Visit
             (Visit 1), ≤0.8 or ≥1.3.

          -  Subject with a history of allergic reaction(s) to one of the different components of
             the dressings or with a contra-indication to the use of one of these dressings.

          -  Known history of alcohol abuse or drug abuse.

          -  Subject linguistically or psychologically unable to understand the information given
             and to provide informed consent.

          -  Subject participating in or who participated in another clinical study within 4 weeks
             prior to the Inclusion Visit (Visit 1).

          -  Subject not covered by or not a beneficiary of the Social Security system.

          -  Subject deprived of his freedom as the result of a legal or administrative decision or
             subject to legal guardianship.

          -  Any other reason, in the investigator's opinion, that prohibits the inclusion of the
             subject into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger Lesaunier, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mylan Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility ID ORG-001183</name>
      <address>
        <city>Angoulème</city>
        <zip>16000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000857</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000853</name>
      <address>
        <city>Asnieres</city>
        <zip>92600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000981</name>
      <address>
        <city>Beaune</city>
        <zip>21200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000844</name>
      <address>
        <city>Boulogne sur Mer</city>
        <zip>62200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000869</name>
      <address>
        <city>Bourgoin Jallieu</city>
        <zip>38300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001215</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001181</name>
      <address>
        <city>Figeac</city>
        <zip>46100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001081</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000850</name>
      <address>
        <city>Hazebrouck</city>
        <zip>59190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000855</name>
      <address>
        <city>Lattes</city>
        <zip>34970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000859</name>
      <address>
        <city>Laxou</city>
        <zip>54520</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000830</name>
      <address>
        <city>Lyon</city>
        <zip>69007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-001362</name>
      <address>
        <city>Melun</city>
        <zip>77000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001182</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000836</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ORG-001361</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000831</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000832</name>
      <address>
        <city>Paris</city>
        <zip>75116</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000856</name>
      <address>
        <city>Pezenas</city>
        <zip>34120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001082</name>
      <address>
        <city>Saint Aubin Sur Scie</city>
        <zip>76550</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000865</name>
      <address>
        <city>Saint Maur</city>
        <zip>94100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000845</name>
      <address>
        <city>Tarare</city>
        <zip>69170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001216</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001083</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000862</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-000835</name>
      <address>
        <city>Vincennes</city>
        <zip>94300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>March 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2019</results_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-inferiority</keyword>
  <keyword>randomized</keyword>
  <keyword>TulleGras</keyword>
  <keyword>Urgotul</keyword>
  <keyword>pain</keyword>
  <keyword>venous leg ulcer</keyword>
  <keyword>healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TulleGras MS - Urgotul</title>
          <description>Cross-over period: one dressing of TulleGras M.S. for two days, then one dressing of Urgotul for two days; Follow-up period: Urgotul for a maximum duration of 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Urgotul - TulleGras MS</title>
          <description>Cross-over period: one dressing of Urgotul for two days, then one dressing of TulleGras M.S. for two days; Follow-up period: TulleGras M.S. for a maximum duration of 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TulleGras MS - Urgotul</title>
          <description>Cross-over period: one dressing of TulleGras M.S. for two days, then one dressing of Urgotul for two days; Follow-up period: Urgotul for a maximum duration of 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Urgotul - TulleGras M.S.</title>
          <description>Cross-over period: one dressing of Urgotul for two days, then one dressing of TulleGras M.S. for two days; Follow-up period: TulleGras M.S. for a maximum duration of 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.3" spread="10.5"/>
                    <measurement group_id="B2" value="77.5" spread="13.7"/>
                    <measurement group_id="B3" value="77.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity at Removal of the Primary Dressing, Evaluated by the Subject Just After Removal</title>
        <description>Pain intensity experienced by subjects associated to removal of each study primary dressings during the care, assessed at of the Cross-over Period on a visual analogue scale (VAS). The VAS was provided as a 100 mm, non-graduated horizontal line, with extremities indicating &quot; no pain &quot; (0) and &quot; extreme pain &quot; (100). The subject responded by drawing a vertical line to assess the pain intensity he/she experienced at the time of removal of the primary wound dressing.</description>
        <time_frame>at the time of dressing removal on Day 2 (Visit 2) and Day 4 (Visit 3)</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>TulleGras M.S.</title>
            <description>TulleGras M.S.: Sterile dressing that consists of viscose tissue coated with mineral vaseline</description>
          </group>
          <group group_id="O2">
            <title>Urgotul</title>
            <description>Urgotul: sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity at Removal of the Primary Dressing, Evaluated by the Subject Just After Removal</title>
          <description>Pain intensity experienced by subjects associated to removal of each study primary dressings during the care, assessed at of the Cross-over Period on a visual analogue scale (VAS). The VAS was provided as a 100 mm, non-graduated horizontal line, with extremities indicating &quot; no pain &quot; (0) and &quot; extreme pain &quot; (100). The subject responded by drawing a vertical line to assess the pain intensity he/she experienced at the time of removal of the primary wound dressing.</description>
          <population>Per protocol</population>
          <units>units on a scale: 0-100 mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="15.6"/>
                    <measurement group_id="O2" value="11.7" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>An estimate of the difference between the pain felt by patient during the two dressings removals along with a 95% confidence interval (CI) has been derived. If the upper limit of the confidence interval was less than 13 mm, clinical non-inferiority of Tulle Gras versus Urgotul has been demonstrated.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.339</ci_lower_limit>
            <ci_upper_limit>1.864</ci_upper_limit>
            <estimate_desc>The pain intensity has been analyzed using analysis of variance (ANOVA). The model for this cross-over study included sequence, period and treatment as fixed effects and subject within sequence as random effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE collection during the whole study + 30 days following last Patient visit</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TulleGras MS - Urgotul</title>
          <description>Cross-over period: one dressing of TulleGras M.S. for two days, then one dressing of Urgotul for two days; Follow-up period: Urgotul for a maximum duration of 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Urgotul - TulleGras MS</title>
          <description>Cross-over period: one dressing of Urgotul for two days, then one dressing of TulleGras M.S. for two days; Follow-up period: TulleGras M.S. for a maximum duration of 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH BY CANCER AGGRAVATION</sub_title>
                <description>D30 after the end of study (LPLV)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTERNATIONAL NORMALIZED RATIO ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FLARE OF POLYARTHRITIS RHEUMATICA ACUTA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>OSTEITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <description>Death after D60 during the study.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>VENOUS ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>BASOCELLULAR CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>AGGRAVATION OF SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LEG PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>TORTICOLLIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>POPLITEAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>VENOUS ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONTACT DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benoit LA ROCHE</name_or_title>
      <organization>Mylan Medical SAS</organization>
      <phone>+33 1 46 25 86 76</phone>
      <email>benoit.la-roche@mylan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

